STOCK TITAN

Dan Daniel becomes Henry Schein (HSIC) independent chair as Bergman retires

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Henry Schein, Inc. reported results of its 2026 Annual Meeting of Stockholders and a leadership change on its Board. Stockholders elected ten incumbent directors for terms expiring in 2027, approved on an advisory basis the 2025 compensation of Named Executive Officers, and ratified BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 26, 2026. A shareholder proposal to Govern by Majority Vote received substantial support but did not pass, with 59,487,608 votes for, 43,707,406 against, 154,122 abstentions and 5,933,309 broker non-votes. The Board elected William K. “Dan” Daniel as Independent Chairman effective May 21, 2026, succeeding long-time director Stanley M. Bergman, who retired from the Board after 44 years and was named Chairman Emeritus. The company notes that its sales reached $13.2 billion in 2025 and have grown at a compound annual rate of approximately 11.0 percent since becoming a public company in 1995.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
2025 Sales $13.2 billion Company sales in 2025
Long-term sales CAGR 11.0 percent Compound annual growth rate since 1995 IPO
Say-on-pay support 101,159,461 For vs 2,110,298 Against Advisory vote on 2025 Named Executive Officer compensation
Auditor ratification votes 107,298,836 For Ratification of BDO USA, P.C. for fiscal year ending December 26, 2026
Majority vote proposal support 59,487,608 For vs 43,707,406 Against Shareholder proposal to Govern by Majority Vote
Employees More than 25,000 Team Schein Members worldwide
Customers served More than 1 million Global customers receiving over 300 solutions
Product selection More than 300,000 products Branded and corporate brand products in main distribution centers
say-on-pay financial
"a proposal to consider approval, by non-binding vote, of the 2025 compensation paid to the Company’s Named Executive Officers ... (commonly known as a “say-on-pay” proposal)"
A say-on-pay is a shareholder vote that gives investors a chance to approve or disapprove a company’s executive compensation packages, typically held at annual meetings. It matters because the vote signals investor satisfaction with how leaders are paid—like customers rating how well managers are rewarded—and can push boards to change pay plans, reducing governance risk and affecting investor confidence and stock value even though the vote is usually advisory rather than legally binding.
independent registered public accounting firm financial
"a proposal to consider the ratification of the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 26, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Majority Vote regulatory
"a proposal to consider approval, by non-binding vote, of a shareholder proposal to Govern by Majority Vote"
Strategic Partnership Agreement financial
"risks related to the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. entered into in January 2025"
EU Medical Device Regulation regulatory
"risks associated with the EU Medical Device Regulation"
EU Medical Device Regulation is the rulebook the European Union uses to approve, monitor and track medical devices sold across its member countries, covering safety tests, documentation and post‑market checks. It matters to investors because it shapes how quickly a device can reach patients, how much companies must spend to comply, and the legal risk of recalls or sales limits—like a tougher safety inspection for cars that can delay launches or force costly redesigns, affecting revenue and valuation.
forward-looking statements regulatory
"we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
HENRY SCHEIN INC false 0001000228 0001000228 2026-05-21 2026-05-21
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 21, 2026

 

 

Henry Schein, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   0-27078   11-3136595
(State or other jurisdiction
of incorporation)
 

(Commission

File Number)

  (IRS Employer
Identification No.)

 

135 Duryea RoadMelvilleNew York   11747
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (631) 843-5500

 

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $.01 per share   HSIC   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 5.07

Submission of Matters to a Vote of Security Holders.

On May 21, 2026, at the Henry Schein, Inc. (the “Company”) 2026 Annual Meeting of Stockholders (the “Annual Meeting”), the Company’s stockholders considered: (1) a proposal to consider approval of the election of ten incumbent directors of the Company for terms expiring in 2027; (2) a proposal to consider approval, by non-binding vote, of the 2025 compensation paid to the Company’s Named Executive Officers (as defined in the proxy statement) (commonly known as a “say-on-pay” proposal); (3) a proposal to consider the ratification of the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 26, 2026; and (4) a proposal to consider approval, by non-binding vote, of a shareholder proposal to Govern by Majority Vote. The voting results at the Annual Meeting, with respect to each of the matters described above, are set forth below.

 

  1.

The ten incumbent directors of the Company were elected to serve for terms expiring in 2027 based upon the following votes:

 

     For      Against      Abstain      Broker
Non-Votes
 

Mohamad Ali

     102,451,460        776,720        120,956        5,933,309  

William K. “Dan” Daniel

     99,760,754        3,561,487        26,895        5,933,309  

Deborah Derby

     102,226,374        1,032,737        90,025        5,933,309  

Carole T. Faig

     103,187,930        106,503        54,703        5,933,309  

Kurt P. Kuehn

     102,824,264        496,439        28,433        5,933,309  

Philip A. Laskawy

     97,174,831        6,158,597        15,708        5,933,309  

Max Lin

     79,900,114        23,411,010        38,012        5,933,309  

Frederick M. Lowery

     103,001,977        332,786        14,373        5,933,309  

Anne H. Margulies

     103,199,853        93,763        55,520        5,933,309  

Reed V. Tuckson, M.D., FACP

     103,198,021        107,489        43,626        5,933,309  

 

  2.

The 2025 compensation paid to the Company’s Named Executive Officers, commonly known as the “say-on-pay” proposal, was approved, by non-binding vote, based upon the following votes:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

101,159,461   2,110,298   79,377   5,933,309

 

  3.

The selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 26, 2026 was ratified based upon the following votes:

 

For

 

Against

 

Abstain

107,298,836   1,805,825   177,784

 

  4.

The shareholder proposal to Govern by Majority Vote was approved, by non-binding vote, based upon the following votes:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

59,487,608   43,707,406   154,122   5,933,309

 

Item 7.01.

Regulation FD.

On May 22, 2026, the Company issued a press release (the “Press Release”) announcing the election of William K. “Dan” Daniel as Independent Chairman of the Company’s Board of Directors. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 and the Press Release attached as Exhibit 99.1 are considered furnished to the Securities and Exchange Commission and are not deemed filed for purposes of Section 18 of the Exchange Act.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

99.1    Press Release, dated May 22, 2026
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

HENRY SCHEIN, INC.

(Registrant)

Date: May 22, 2026   By:  

/s/ Kelly Murphy

      Kelly Murphy
      Senior Vice President and General Counsel

Exhibit 99.1

 

LOGO

LOGO

FOR IMMEDIATE RELEASE

HENRY SCHEIN ANNOUNCES THE ELECTION OF WILLIAM K. “DAN” DANIEL AS INDEPENDENT CHAIRMAN OF THE BOARD

MELVILLE, N.Y., May 22, 2026 – Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. “Dan” Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary contributions to the Company.

Mr. Daniel joined the Henry Schein Board of Directors in May 2025. He possesses decades of board and global executive leadership experience in healthcare and industrial sectors, including serving for 14 years as Executive Vice President at Danaher Corporation (NYSE: DHR), where he oversaw multiple business segments including Danaher’s dental portfolio. Mr. Daniel also played a key role in advancing Danaher’s business systems and culture, while also serving as a Board Director at Envista Holdings Corporation (NYSE: NVST) when it was spun off from Danaher.

“I am deeply honored to assume the role of Chairman and am committed to building upon the extraordinary foundation that Stan Bergman and Team Schein established over his tenure,” said Mr. Daniel. “Stan’s strategic leadership, sound judgment, and unwavering dedication to Henry Schein’s mission have helped shape this company into the leading industry provider of products, services, and technology platforms for healthcare customers. His contributions to shareholders, customers, supplier partners, Team Schein Members, and society are profound and enduring. I look forward to supporting this legacy with the Board as we enter an exciting new chapter of growth.”

Stan Bergman said, “It has been an honor to lead Team Schein and serve as Chairman of the Board. I have worked with Dan for many years and have huge respect for his business acumen and leadership. The Company is in good hands, and I look forward to continuing to support Henry Schein’s continuing success as Chairman Emeritus.”

Fred Lowery, Chief Executive Officer of Henry Schein, said, “On behalf of Team Schein, I want to express our profound gratitude to Stan for his remarkable contributions over more than four decades. His transformative leadership positions the Company for tremendous growth, and we wish Stan all the best in this well-deserved next chapter. I am also delighted to welcome Dan Daniel as Chairman of the Board. Dan’s deep understanding of our business and the markets we serve, combined with his distinguished track record, will be instrumental as we execute on our long-term strategy of building the healthcare industry’s most trusted and comprehensive platform of integrated solutions—empowering practitioners to optimize their business operations while advancing the quality, accessibility, and outcomes of patient care.”

 

- 1 -


About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a products, services, and technology platforms company for healthcare customers. With more than 25,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our main distribution centers.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 34 countries and territories. The Company’s sales reached $13.2 billion in 2025, and have grown at a compound annual rate of approximately 11.0 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and @HenrySchein on X.

Cautionary Note Regarding Forward-Looking Statements

In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable terms. A fuller discussion of our operations, financial condition and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: our dependence on third parties for the manufacture and supply of our products and where we manufacture products, our dependence on third parties for raw materials or purchased components; risks relating to the achievement of our strategic growth objectives, including anticipated results of restructuring and value creation initiatives; risks related to the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. entered into in January 2025; transitions in senior company leadership and the Board of Directors (including, without limitation, the transition to a new Chief Executive Officer and a new Chairman of the Board of Directors); our ability to develop or acquire and maintain and protect new products (particularly technology and specialty products) and services and utilize new technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions and joint ventures, including the failure to achieve anticipated synergies/benefits, as well as significant demands on our operations, information systems, legal, regulatory, compliance, financial and human resources functions

 

- 2 -


in connection with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; risks related to activist investors; security risks associated with our information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident); effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; political, economic, and regulatory influences on the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers, and increases in fuel and energy costs; changes in laws and policies governing manufacturing, development and investment in territories and countries where we do business; general global and domestic macro-economic and political conditions, including inflation, deflation, recession, unemployment (and corresponding increase in under-insured populations), consumer confidence, sovereign debt levels, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies and changes to other economic indicators failure to comply with existing and future regulatory requirements, including relating to health care; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation, changes in tax rates and availability of certain tax deductions; risks related to product liability, intellectual property and other claims; risks associated with customs policies or legislative import restrictions; risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or man-made disasters; risks associated with our global operations; the threat or outbreak of war (including, without limitation, geopolitical wars), terrorism or public unrest (including, without limitation, the wars in Ukraine and Iran, the Israel-Gaza war and other unrest and threats in the Middle East and the possibility of a wider European or global conflict); changes to laws and policies governing foreign trade, tariffs and sanctions or greater restrictions on imports and exports, including changes to international trade agreements and the current imposition of (and the potential for additional) tariffs by the U.S. on numerous countries and retaliatory tariffs; supply chain disruption; litigation risks; new or unanticipated litigation developments and the status of litigation matters; our dependence on our senior management, employee hiring and retention, increases in labor costs or health care costs, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law.

 

CONTACTS:

Investors

 

Ronald N. South

Senior Vice President and Chief Financial Officer

ronald.south@henryschein.com

(631) 843-5500

 

Graham Stanley

Vice President, Investor Relations and Strategic Financial Project Officer

graham.stanley@henryschein.com

(631) 843-5500

 

Media

 

Tim Vassilakos

Vice President, Global Corporate Communications

timothy.vassilakos@henryschein.com

(516) 510-0926

 

- 3 -

FAQ

What did Henry Schein (HSIC) stockholders approve at the 2026 Annual Meeting?

Stockholders elected ten incumbent directors for terms expiring in 2027, approved on an advisory basis 2025 executive compensation, and ratified BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 26, 2026.

How did Henry Schein (HSIC) stockholders vote on the say-on-pay proposal for 2025 compensation?

Stockholders approved, by non-binding vote, the 2025 compensation of Henry Schein’s Named Executive Officers. The proposal received 101,159,461 votes for, 2,110,298 votes against, 79,377 abstentions and 5,933,309 broker non-votes, indicating strong support for the company’s executive pay program.

What were the results of the Henry Schein (HSIC) shareholder proposal to Govern by Majority Vote?

The shareholder proposal to Govern by Majority Vote did not pass. It received 59,487,608 votes for, 43,707,406 against, 154,122 abstentions and 5,933,309 broker non-votes, showing significant but insufficient support to change the company’s governance structure via this proposal.

Who is Henry Schein’s new Independent Chairman of the Board?

William K. “Dan” Daniel was elected Independent Chairman of Henry Schein’s Board, effective May 21, 2026. He succeeds Stanley M. Bergman, who retired from the Board after 44 years and was named Chairman Emeritus in recognition of his long-term contributions to the company.

What governance change occurred at Henry Schein (HSIC) with Stan Bergman’s retirement?

Stanley M. Bergman retired from Henry Schein’s Board after 44 years as a director and Chairman. The Board elected William K. “Dan” Daniel as Independent Chairman, while Mr. Bergman was named Chairman Emeritus, reflecting a planned leadership transition at the board level.

How large is Henry Schein’s business based on recent reported sales?

Henry Schein reported 2025 sales of $13.2 billion. The company states its sales have grown at a compound annual rate of approximately 11.0 percent since it became a public company in 1995, highlighting long-term revenue expansion across its global healthcare solutions business.

Filing Exhibits & Attachments

4 documents